Prosecution Insights
Last updated: April 19, 2026
Application No. 14/848,032

MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF

Non-Final OA §112
Filed
Sep 08, 2015
Examiner
MONTGOMERY, ANN Y
Art Unit
1678
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Labrador Diagnostics LLC
OA Round
14 (Non-Final)
70%
Grant Probability
Favorable
14-15
OA Rounds
3y 10m
To Grant
96%
With Interview

Examiner Intelligence

Grants 70% — above average
70%
Career Allow Rate
457 granted / 657 resolved
+9.6% vs TC avg
Strong +26% interview lift
Without
With
+26.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
24 currently pending
Career history
681
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
44.3%
+4.3% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
17.9%
-22.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 657 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. New claim 133 recites the limitation "the plurality of reagent wells" in line 1. There is insufficient antecedent basis for this limitation in the claim. [Examiner placed a telephone call to Applicant’s attorney, Carson Smith, to offer an Examiner’s amendment, but Applicant’s attorney stated that an Office action can be submitted as more time would be needed for a response.] Allowable Subject Matter Claims 109-115, 117-120, and 125-132 are allowed. Claim 133 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. The following is an examiner’s statement of reasons for allowance. It was not found in the prior art search a teaching or suggestion for a system comprising: the combination of a cartridge comprising wells (i.e., a sample well and reagent well); an assay unit comprising immobilized binding reagent, wherein the cartridge is movable independent of the assay unit; a translational stage configured to move the cartridge relative to the assay unit to place the sample well into fluid communication with the assay unit, and to place the reagent well into fluid communication with the assay unit; an automated fluid transfer device configured to engage the enlarged second end of the assay unit and to direct transfer of the sample from the sample well and the reagent from the reagent well into the assay unit such that a reaction occurs within the assay unit that yields a signal indicative of a presence of the analyte; and a detection assembly arranged proximate to the assay unit when the assay unit is engaged with the automated fluid transfer device such that the detection assembly is configured to detect the signal within the assay unit. Examiner notes that the previously cited reference, Kumar (US 5,976,896), does not disclose or suggest in one embodiment wells or containers (equivalent to assay or reagent units) that move to the capillary tubes (equivalent to assay units) as well as a detector that is arranged proximate to the assay unit to detect a signal within the assay unit when the assay unit is engaged with the automated fluid transfer device. For example, the embodiment in Kumar in column 35, line 66 to column 36, line 16, does not have wells or sample tray that move to the capillaries (assay unit). Kumar discloses that the capillary tubes are provided in a circular manner around a cylinder and rotated to present a particular tube to a sample source or to a fluid source for washing or adding reagent, and the cylinder can also rotate to present a capillary tube to a signal generation and detection means. “Alternatively, the cylinder can cooperate with a multiwelled circular sample tray for serial or simultaneous sample removal and/or washing and expelling of fluid and even multiple signal generation and detection means. The circularly spaced apart capillary tubes can encircle a central syringe that is in fluid communication with the capillary tubes and draws fluid into the capillary tubes and/or advances fluid from the capillary tubes into any chambers and/or reaction sites on the surface of the capillary tubes.” (Kumar, in col. 35, line 66 to col. 36, line 16). Thus there is no teaching or suggestion in this embodiment for moving the wells or reagent/sample containers to the capillary tubes in Kumar. In the embodiment in column 32, lines 20-46 wherein the sample tray (equivalent to Applicant’s cartridge with sample or reagent units) are moved to the cartridge of capillaries, the detector is not arranged to detect a signal within the assay unit when the assay unit is engaged with the fluid transfer device, since the syringe (210) (equivalent to a fluid transfer device) is provided at a separate location from the detection station (203) (see fig. 13, for example.) Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ann Montgomery whose telephone number is (571)272-0894. The examiner can normally be reached Mon-Fri, 9-5:30 PM PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Greg Emch can be reached at 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Ann Montgomery/Primary Examiner, Art Unit 1678
Read full office action

Prosecution Timeline

Sep 08, 2015
Application Filed
Sep 08, 2015
Response after Non-Final Action
Nov 30, 2015
Non-Final Rejection — §112
Mar 02, 2016
Applicant Interview (Telephonic)
Mar 03, 2016
Response Filed
Jun 14, 2016
Non-Final Rejection — §112
Sep 15, 2016
Response Filed
Oct 16, 2016
Final Rejection — §112
Mar 20, 2017
Request for Continued Examination
Mar 22, 2017
Response after Non-Final Action
Jun 16, 2017
Non-Final Rejection — §112
Dec 22, 2017
Response Filed
Apr 02, 2018
Final Rejection — §112
Apr 04, 2018
Applicant Interview (Telephonic)
Apr 04, 2018
Applicant Interview
Jul 16, 2018
Applicant Interview (Telephonic)
Jul 16, 2018
Applicant Interview
Aug 06, 2018
Request for Continued Examination
Aug 08, 2018
Response after Non-Final Action
Oct 30, 2018
Non-Final Rejection — §112
Nov 09, 2018
Response Filed
Mar 27, 2019
Request for Continued Examination
Apr 03, 2019
Response after Non-Final Action
Apr 03, 2019
Response after Non-Final Action
Sep 12, 2019
Request for Continued Examination
Sep 13, 2019
Response after Non-Final Action
Apr 14, 2020
Request for Continued Examination
Apr 23, 2020
Response after Non-Final Action
Jun 07, 2020
Non-Final Rejection — §112
Sep 10, 2020
Response Filed
Dec 11, 2020
Final Rejection — §112
Apr 15, 2021
Request for Continued Examination
Apr 16, 2021
Response after Non-Final Action
Jun 04, 2021
Non-Final Rejection — §112
Oct 13, 2021
Applicant Interview (Telephonic)
Nov 03, 2021
Examiner Interview Summary
Nov 09, 2021
Response Filed
Feb 24, 2022
Final Rejection — §112
Jun 23, 2022
Response after Non-Final Action
Jul 13, 2022
Response after Non-Final Action
Jul 28, 2022
Request for Continued Examination
Aug 02, 2022
Response after Non-Final Action
Aug 26, 2022
Non-Final Rejection — §112
Dec 30, 2022
Response Filed
Mar 05, 2023
Final Rejection — §112
Jun 15, 2023
Request for Continued Examination
Jun 21, 2023
Response after Non-Final Action
Aug 26, 2023
Non-Final Rejection — §112
Jan 31, 2024
Response Filed
Aug 05, 2024
Request for Continued Examination
Aug 06, 2024
Response after Non-Final Action
Aug 06, 2024
Response after Non-Final Action
Mar 19, 2025
Request for Continued Examination
Mar 23, 2025
Response after Non-Final Action
Mar 23, 2025
Response after Non-Final Action
Oct 24, 2025
Request for Continued Examination
Oct 27, 2025
Response after Non-Final Action
Dec 01, 2025
Response after Non-Final Action
Feb 07, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590960
IMMUNOASSAY TEST DEVICE WITH TWO FLUID FLOW PATHS FOR DETECTION AND DIFFERENTIATION OF TWO OR MORE ANALYTES
2y 5m to grant Granted Mar 31, 2026
Patent 12575772
DEVICES AND METHODS FOR BODILY FLUID COLLECTION AND DISTRIBUTION
2y 5m to grant Granted Mar 17, 2026
Patent 12570947
BUFFER PREPARATION AND TRANSFER SYSTEM FOR ANTIBODY DRUG MANUFACTURING PROCESS
2y 5m to grant Granted Mar 10, 2026
Patent 12566183
DETECTION OF BIOMARKERS ON VESICLES FOR THE DIAGNOSIS AND PROGNOSIS OF DISEASES AND DISORDERS
2y 5m to grant Granted Mar 03, 2026
Patent 12560598
CARTRIDGE-BASED AUTOMATED RAPID TEST ANALYZER
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

14-15
Expected OA Rounds
70%
Grant Probability
96%
With Interview (+26.5%)
3y 10m
Median Time to Grant
High
PTA Risk
Based on 657 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month